Akari Therapeutics (AKTX) Non-Current Deferred Tax Liability (2024 - 2026)

Akari Therapeutics' Non-Current Deferred Tax Liability history runs 3 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability fell 24.2% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (down 24.2% YoY), while the FY2025 annual figure was $7.0 million, down 13.53% from the prior year.
• Non-Current Deferred Tax Liability came in at $6.1 million for Q1 2026 at Akari Therapeutics, down from $7.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $8.0 million in Q4 2024 to a low of $6.1 million in Q1 2026.
• A 3-year average of $7.4 million and a median of $7.5 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability fell 13.53% in 2025 and declined 24.2% in 2026, its largest moves.
• Akari Therapeutics' Non-Current Deferred Tax Liability stood at $8.0 million in 2024, then decreased by 13.53% to $7.0 million in 2025, then retreated by 12.34% to $6.1 million in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $6.1 million, $7.0 million, and $7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison